Increase in the Annual Rate of Newly Diagnosed Metastatic Prostate Cancer: A Contemporary Analysis of the Surveillance, Epidemiology and End Results Database

Slides:

Advertisements

Similar presentations

Volume 61, Issue 5, Pages (May 2012)

Advertisements

An Explanatory Case on the Limitations of Lymph Node Staging in Recurrent Prostate Cancer Marco Bandini, Giorgio Gandaglia, Nicola Fossati, Francesco.

Volume 68, Issue 6, Pages (December 2015)

Volume 61, Issue 3, Pages (March 2012)

Volume 62, Issue 3, Pages (September 2012)

Volume 72, Issue 1, Pages (July 2017)

Volume 50, Issue 3, Pages (September 2006)

Volume 68, Issue 2, Pages (August 2015)

Volume 62, Issue 4, Pages (October 2012)

Testosterone Therapy in Men With Prostate Cancer

Volume 58, Issue 1, Pages (July 2010)

Prostate Cancer 2008: Challenges in Diagnosis and Management

The Effect of Other-cause Mortality Adjustment on Access to Alternative Treatment Modalities for Localized Prostate Cancer Among African American Patients

Volume 61, Issue 5, Pages (May 2012)

Volume 51, Issue 6, Pages (June 2007)

Control of Prostate Cancer by Transrectal HIFU in 227 Patients

Volume 73, Issue 3, Pages (March 2018)

Surgically Treated Retroperitoneal Sarcoma: A Population-based Competing Risks Analysis Sebastiano Nazzani, Felix Preisser, Marco Bandini, Michele Marchioni,

Volume 71, Issue 5, Pages (May 2017)

Volume 63, Issue 4, Pages (April 2013)

Tumour Grade, Treatment, and Relative Survival in a Population-based Cohort of Men with Potentially Curable Prostate Cancer Sam Ladjevardi, Gabriel Sandblom,

Volume 67, Issue 2, Pages (February 2015)

Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance Adam B. Weiner, Ruth Etzioni, Scott E. Eggener

Volume 68, Issue 3, Pages (September 2015)

Low-risk Prostate Cancer: Identification, Management, and Outcomes

Laurent Boccon-Gibod European Urology Supplements

Volume 61, Issue 5, Pages (May 2012)

Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases Axel Heidenreich, Nicola Fossati, David Pfister, Nazareno Suardi,

Rectal Injury During Radical Prostatectomy: Focus on Robotic Surgery

Volume 71, Issue 1, Pages (January 2017)

Volume 68, Issue 6, Pages e134-e135 (December 2015)

Volume 59, Issue 1, Pages (January 2011)

Volume 60, Issue 6, Pages (December 2011)

Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based Study Stephen H. Culp, Paul.

Volume 68, Issue 4, Pages (October 2015)

Is It Necessary to Detect All Prostate Cancers in Men with Serum PSA Levels

Volume 50, Issue 5, Pages (November 2006)

Selma Masic, Janet E. Cowan, Samuel L. Washington, Hao G

Volume 72, Issue 4, Pages (October 2017)

Prostate Cancer Nomograms: An Update

What's New in Prostate Cancer: Highlights from Urologic and Oncologic Congresses in 2006 Michel Soulié, Nicolas Mottet, Laurent Salomon, Jacques Irani,

Testicular Cancer Variations in Time and Space in Europe

Volume 66, Issue 6, Pages (December 2014)

The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.

Is Robot-assisted Surgery Contraindicated in the Case of Partial Nephrectomy for Complex Tumours or Relevant Comorbidities? A Comparative Analysis of.

European Urology Oncology

Trend of Adverse Stage Migration in Patients Treated with Radical Prostatectomy for Localized Prostate Cancer Felix Preisser, Michele Marchioni, Sebastiano.

European Urology Oncology

Volume 72, Issue 1, Pages (July 2017)

European Urology is “Your” Journal

Jonathan S. Brajtbord, Michael S. Leapman, Matthew R. Cooperberg

Psychotherapeutic Interventions Targeting Prostate Cancer Patients: A Systematic Review of the Literature Liliana Vartolomei, Shahrokh F. Shariat, Mihai.

Volume 74, Issue 6, Pages (December 2018)

A Multidisciplinary Team Approach for the Optimal Clinical Management of Metastatic Hormone-Refractory Prostate Cancer—Case Study John Fitzpatrick European.

Volume 50, Issue 5, Pages (November 2006)

Prostate Cancer 2008: Challenges in Diagnosis and Management

Volume 54, Issue 1, Pages (July 2008)

The Comparability of Models for Predicting the Risk of a Positive Prostate Biopsy with Prostate-Specific Antigen Alone: A Systematic Review Fritz Schröder,

Not All Multiparametric Magnetic Resonance Imaging–targeted Biopsies Are Equal: The Impact of the Type of Approach and Operator Expertise on the Detection.

European Urology Oncology

Volume 53, Issue 2, Pages (February 2008)

Volume 54, Issue 3, Pages (September 2008)

Oncoforum Urology: Prostate Cancer 2008 at a Glance

European Urology Oncology

Epidemiology and Demographics of Prostatitis

Does PSA Testing Influence the Natural History of Prostate Cancer?

European Urology Oncology

European Urology Oncology

How to Treat a Patient with T1 High-grade Disease and No Tumour on Repeat Transurethral Resection of the Bladder? Shahrokh Shariat, Paolo Gontero, James.

European Urology Oncology

Presentation transcript:

Increase in the Annual Rate of Newly Diagnosed Metastatic Prostate Cancer: A Contemporary Analysis of the Surveillance, Epidemiology and End Results Database Marco Bandini, Elio Mazzone, Felix Preisser, Sebastiano Nazzani, Emanuele Zaffuto, Michele Marchioni, Zhe Tian, Raisa S. Pompe, Derya Tilki, Markus Graefen, Shahrokh F. Shariat, Francesco Montorsi, Fred Saad, Alberto Briganti, Pierre Karakiewicz European Urology Oncology Volume 1, Issue 4, Pages 314-320 (September 2018) DOI: 10.1016/j.euo.2018.04.013 Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 1 Age-adjusted temporal trends during 2004–2014 for newly diagnosed metastatic prostate cancer per 100 000 population. European Urology Oncology 2018 1, 314-320DOI: (10.1016/j.euo.2018.04.013) Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 2 Annual trends (LOWESS) for (A) baseline prostate-specific antigen (PSA; <50, 50–98, and >98ng/ml), (B) biopsy Gleason score (GS ≤6, GS 7, GS 8–10), (C) clinical T stage (cT1, cT2, and cT3–4), (D) metastasis substage (M1a, M1b, and M1c), and (E) age at diagnosis. European Urology Oncology 2018 1, 314-320DOI: (10.1016/j.euo.2018.04.013) Copyright © 2018 European Association of Urology Terms and Conditions